Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia

Clinical and Investigative Medicine

Volumn 32, Issue 2, 2009, Pages

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   D'Angelo, Angela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Fogari, Elena ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   Palumbo, Ilaria ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FIBRINOGEN; GELATINASE A; GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 65249183907     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Sierevogel MJ, Pasterkamp G, de Kleijn DP, Strauss BH. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 2003;9(13):1033-1040.
2. Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 2003;26:55-9.
3. Galis ZS, Muszynski M, Sukhova GK, Simon- Morrissey E, Lybbi P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytoki- nes and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995;748:501-7.
4. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma level of matrix metalloproteina- se-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-7.
5. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Am Coll Cardiol 1998;32:368-72.
6. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997;78:2784.
7. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristen- son M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population.PLoS ONE 2008;3:e1774.
8. Derosa G, Cicero AF, Scalise F, et al. Metalloproteinase-2 and -9 in Diabetic and Nondia- betic Subjects during Acute Coronary Syndromes. Endothelium 2007;14:45-51.
9. Derosa G, Cicero AF, Scalise F, et al. Metalloprote- inases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium 2007;14:175-83.
10. Derosa G, D'Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. En- dothelium 2006;13:227-31.
11. Derosa G, Avanzini MA, Geroldi D, et al. Matrix met- alloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 2005;70:119-25.
12. Derosa G, D'Angelo A, Tinelli C, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007;33:129-34.
13. Derosa G, Ferrari I, D'Angelo A, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008;15:219-24.
14. El Messal M, Beaudeux JL, Drissi A, et al. Elevated serum levels of proinflammatory cytokines and bio- markers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin Chim Acta 2006;366:185-9.
15. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91.
16. Gotto AMJr, Amarenco P, Assman G, et al. The ILIB Lipid Handbook for Clinical Practice: Dyslipidemia and Coronary Heart Disease. 3rd Edition, New York, International Lipid Information Bureau, 2003, pp 1-242.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
18. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diab Med 1999;16:716-30.
19. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6.
20. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978;15:121-30.
21. Wahlefeld AW. Methods of Enzymatic Analysis. In: Bermeyer HU (ed), Triglycerides determination after enzymatic hydrolysis. 2nd English ed., Academic Press, Inc, New York, 1974, pp 18-31.
22. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
24. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992;2:427-38.
25. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1959;17:237-46.
26. Araki A, Sako Y. Determination of free and total ho- mocysteine in human plasma by high performance chromatography with fluorescence detection. J Chro-matography 1987;422:43-52.
27. Rifai N, Tracy RP, Ridker PM. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay. Clin Chem 1999;45:2136-41.
28. Scanu AM, Scandian L. Lipoprotein(a): structure, biology and clinical relevance. Adv Intern Med 1991;36:249-70.
29. Uterman G, Weber W. Protein composition of lipopro- tein (a). J Clin Invest 1987;80:458-65.
30. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001;7:941-6.
31. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoas- say for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 1993;221:91-103.
32. Fujimoto N, Hosokawa N, Iwata K, Shinya T, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoas- say for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/ type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 1994;231:79-88.
33. Clark IM, Powell LK, Wright JK, Cawston TE. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 1991;11:76-85.
34. Fujimoto N, Zhang J, Iwata K, Shinya T, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoas- say for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta 1993;220:31-45.
35. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008;156:112-9.
36. Jia L, Fu M, Tian Y, et al. Alterations of high-density lipoprotein subclasses in hypercholesterolemia and combined hyperlipidemia. Int J Cardiol 2007;120:331-7.
37. Viles-Gonzalez JF, Fuster V, Badimon JJ. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 2006;6:489-99.
38. Cicero AF, Derosa G, Manca M, Bove M, Borghi C, Gaddi AV. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hy- perlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 2007;14:193-8.
39. Xu XP, Meisel SR, Ong JM, et al. Oxidized low- density lipoprotein regulates matrix metalloproteinase- 9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999;99:993-8.
40. Ardans JA, Economou AP, Martinson JM Jr, Zhou M, Wahl LM. Oxidized low-density and high-density lipo- proteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. J Leukoc Biol 2002;71:1012-8.
41. Manginas A, Bei E, Chaidaroglou A, et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 2005;28:182-6.
42. Welsh P, Whincup PH, Papacosta O, et al. Serum matrix metalloproteinase-9 and coronary heart disease: aprospective study in middle-aged men. Q J Med 2008;101:785-91.
43. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem Biophys Res Commun. 1999;257:79-83.
44. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6.
45. Cheng KH, Chu CS, Lee KT, et al. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 2008;32:268-74.
46. Cheng M, Hashmi S, Mao X, Zeng QT. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 2008;24:385-90.
47. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin.Trends Cardiovasc Med 2006;16:141-6.
48. Pischon T., Rimm EB. Adiponectin: a promising marker for cardiovascular disease. Clin Chem 2006;52:797-9.
49. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
50. Vincenti MP. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase genes. Methods Mol Biol 2001;151:121-48.